Merck completes acquisition of Sentinel parasite products
With the completion of this deal, Merck Animal Health now offers products that address all of the most common internal and external parasites affecting dogs.
Merck Animal Health has completed its acquisition of US rights to Sentinel Flavor Tabs (milbemycin oxime/lufenuron) and Sentinel Spectrum Chews (milbemycin oxime/lufenuron/praziquantel)—products that target common intestinal parasites, according to a company release.
The announcement comes less than 2 months after Merck Animal Health and Virbac agreed on a price tag of about $400 million.
With this acquisition, Merck now offers a comprehensive range of products that address the seven most common parasites that affect dogs: ticks, fleas, roundworms, hookworms, whipworms, tapeworms, and heartworms.
“Our veterinary medicines, including parasiticides, and vaccines continue to transform the animal health industry and further solidify our position in the US Companion Animal category,” said Merck Animal Health President Rick DeLuca, in the release.
For more information about this acquisition, visit merck-animal-health-usa.com.